Reynoldson & Reynoldson Chrtd Optometrist Medicare: Medicare Enrolled Practice Location: 1208 W 8th St, Junction City, KS 66441 Phone: 785-238-1104 Fax: 785-238-2325 |
Dr. Scott B Mcclain, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1025 W 6th St, Junction City, KS 66441 Phone: 785-223-5777 |
Dr. Raymond Joseph Schmidt, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 338 W 7th St, Junction City, KS 66441 Phone: 785-762-4422 Fax: 785-762-4292 |
Christina A Windhorst, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1025 W 6th St, Junction City, KS 66441 Phone: 785-223-5777 Fax: 785-223-0257 |
The Eyedoctors Optometrist Medicare: Medicare Enrolled Practice Location: 1025 W 6th St, Junction City, KS 66441 Phone: 636-200-4393 Fax: 785-223-0257 |
Dr. Guy M Reynoldson, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1208 W 8th St, Junction City, KS 66441 Phone: 785-238-1104 Fax: 785-238-2325 |
News Archive
In new and extensive clinical trials an experimental blood thinner called rivaroxaban is at least as good at preventing strokes as the drug warfarin – that has been the most widely used agent for the past five decades in people with erratic heartbeats called atrial fibrillations. Researchers said this Monday that this drug also sharply reduces the risk of major bleeding that is seen with warfarin.
A new study by researchers at the University of Oregon published today in the journal Neuron describes a brainstem circuit in mice that may help explain how active movement impacts the way the brain processes sensory information.
Scientists at UCL have discovered how immune cells, essential for tackling life-threatening infections and cancers, are able to 'recycle' material within themselves in order to stay healthy and function, a breakthrough finding which could lead to more effective immunotherapies.
According to the current state of knowledge, there are no cases that have shown evidence of humans being infected with the novel coronavirus via the consumption of contaminated food.
Clinical trials using patients' own immune cells to target tumors have yielded promising results. However, this approach usually works only if the patients also receive large doses of drugs designed to help immune cells multiply rapidly, and those drugs have life-threatening side effects. Now a team of MIT engineers has devised a way to deliver the necessary drugs by smuggling them on the backs of the cells sent in to fight the tumor. That way, the drugs reach only their intended targets, greatly reducing the risk to the patient.
› Verified 9 days ago